Medigen Vaccine Biologics Corp (高端疫苗) has obtained certification to market its COVID-19 reagent, which uses a polymerase chain reaction (PCR) technique, in the eurozone.
“The approval gave us access to the European market, but as our testing kits are produced in Taiwan, we need to gain marketing approval from the Taiwan Food and Drug Administration before exporting those products,” spokesman Leo Lee (李思賢) told the Taipei Times by telephone on Monday.
The crisis could accelerate the agency’s review, compared with at least one year in the past, Lee said.
Given the shortage of coronavirus testing kits, foreign buyers have shown an interest in the firm’s products, he said, adding that Medigen’s local plant has produced some kits.
For an in vitro diagnostic device, the firm spent one month gaining CE marking certification, which is required for products sold in the European Economic Area, under an emergency-use program initiated by the European Commission.
Medigen’s diagnostic reagent was the latest to obtain the certification, after products manufactured by GeneReach Biotechnology Corp (瑞基海洋) and General Biologicals Corp (普生).
Like the other companies’ products, Medigen’s reagent gives results in about 80 minutes, with an accuracy rate of 95 percent, Lee said.
As some people infected with COVID-19 have shown false negatives, the public has questioned the accuracy of the testing kits that are available.
“The false negatives are not the result of a failure on the part of the testing kits, as most medical devices are sensitive and accurate. It is more likely attributable to how the samples are collected,” Lee said.
If the viral load on a throat swab is too low, the result cannot be positive, so it is important to conduct the tests several times, he said.
Medigen is not concerned that competition in the coronavirus reagent business could heat up too much as foreign companies develop antibody testing kits, Lee said, adding that PCR testing kits identify the coronavirus, while the antibody blood tests determine whether a person’s immune system has developed antibodies against the virus.
“The former determines if those tested would infect others, while the latter determines if the person has recovered and can come out of isolation,” Lee said.
The two products are used in a complementary way, he added.
Separately, active pharmaceutical ingredient maker Formosa Laboratories Inc (台耀化學) on Monday said that it collaborated with National Yang-Ming University in Taipei, National Chiao Tung University in Hsinchu and Taipei Veterans General Hospital in synthesizing 168g of remdesivir, a new antiviral drug by US-based Gilead Sciences Inc that targets infectious diseases such as Ebola and SARS, and that has shown some effectiveness against COVID-19.
Formosa Laboratories told local media that it has spent NT$4 million (US$133,174) on capacity to produce remdesivir.
The firm has also funded research on the production of favipiravir, the main ingredient in the influenza drug Avigan, which was developed by Fujifilm Holdings Corp in Japan and is being tested as a potential treatment for COVID-19.
Additional reporting by staff writer
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
ARTIFICIAL INTELLIGENCE: The chipmaker last month raised its capital spending by 28 percent for this year to NT$32 billion from a previous estimate of NT$25 billion Contract chipmaker Powerchip Semiconductor Manufacturing Corp (力積電子) yesterday launched a new 12-inch fab, tapping into advanced chip-on-wafer-on-substrate (CoWoS) packaging technology to support rising demand for artificial intelligence (AI) devices. Powerchip is to offer interposers, one of three parts in CoWoS packaging technology, with shipments scheduled for the second half of this year, Powerchip chairman Frank Huang (黃崇仁) told reporters on the sidelines of a fab inauguration ceremony in the Tongluo Science Park (銅鑼科學園區) in Miaoli County yesterday. “We are working with customers to supply CoWoS-related business, utilizing part of this new fab’s capacity,” Huang said, adding that Powerchip intended to bridge
Microsoft Corp yesterday said that it would create Thailand’s first data center region to boost cloud and artificial intelligence (AI) infrastructure, promising AI training to more than 100,000 people to develop tech. Bangkok is a key economic player in Southeast Asia, but it has lagged behind Indonesia and Singapore when it comes to the tech industry. Thailand has an “incredible opportunity to build a digital-first, AI-powered future,” Microsoft chairman and chief executive officer Satya Nadella said at an event in Bangkok. Data center regions are physical locations that store computing infrastructure, allowing secure and reliable access to cloud platforms. The global embrace of AI
Qualcomm Inc, the world’s biggest seller of smartphone processors, gave an upbeat forecast for sales and profit in the current period, suggesting demand for handsets is increasing after a two-year slump. Revenue in the three months ended in June will be US$8.8 billion to US$9.6 billion, the company said in a statement Wednesday. Excluding certain items, earnings will be US$2.15 to US$2.35 a share. Analysts had projected sales of US$9.08 billion and earnings of US$2.16 a share. The outlook signals that the smartphone market has begun to bounce back, tracking with Qualcomm’s forecast that demand would gradually recover this year. The San